2.50
Hdl Handle:
http://hdl.handle.net/10143/39973
Title:
Omfang av sprøytemisbruk i Norge
Authors:
Bretteville-Jensen, Anne Line; Amundsen, Ellen J.
Citation:
SIRUS-rapport 5/2006
Additional Links:
http://www.sirus.no/internett/narkotika/publication/309.html

Full metadata record

DC FieldValue Language
dc.contributor.authorBretteville-Jensen, Anne Line-
dc.contributor.authorAmundsen, Ellen J.-
dc.date.accessioned2008-10-30T15:48:29Z-
dc.date.available2008-10-30T15:48:29Z-
dc.date.issued2007-02-
dc.identifier.citationSIRUS-rapport 5/2006en
dc.identifier.issn1502-8178-
dc.identifier.urihttp://hdl.handle.net/10143/39973-
dc.description.abstractNORSK SAMMENDRAG: Rapporten presenterer beregninger av omfang av sprøytemisbruk i Norge og hvordan dette har utviklet seg fra 1997 til 2004. Beregningene viser følgende: Antall sprøytemisbrukere i Norge nådde en topp i 2001, for så å gå ned til 2003. Etter dette har det skjedd en utflating til 2005. Det er ett sted mellom 8 200 og 12 500 misbrukere i Norge i 2005. Den viktigste årsaken til fallet er trolig at mange sprøytemisbrukere ble tatt inn i legemiddelassistert rehabilitering (LAR). Debutalderen har økt, nå er gjennomsnittet 26,9 år. Det er større aldersspredning på de som begynner nå enn tidligere. Det er ingen tegn til økt rekruttering til sprøytemisbruk. Gjennomsnittsalderen blant misbrukerne er økende. Ved sprøyteutdelingen i Oslo økte snittalderen fra 29 år i 1993 til 36 år i 2006. Årsaken er trolig at flere starter senere og at mange av de som startet tidlig fremdeles er misbrukere. Kvinneandelen blant misbrukerne er synkende. I dag er den mellom 25-30 prosent mot rundt 30-35 prosent på begynnelsen av 1990-tallet. Oslos andel av sprøytemisbrukere har sunket etter 1999. Men antall sprøytemisbrukere pr innbygger er fortsatt større i Oslo enn landet ellers. Det er ikke mulig å gi eksakte tall over sprøytemisbruk, fordi dette er en tabubelagt og illegal aktivitet som ikke fanges opp av vanlige spørreundersøkelser. Tallberegningene i rapporten bygger bl.a. på oversikter over narkotikadødsfall, dødelighet blant sprøytemisbrukere, funn av morfin i blodet hos bilførere, pasienter i legemiddelassistert behandling og rapporter om sprøytemisbruk fra sosialtjenesten i kommunene og lokale politikamre.en
dc.description.abstractENGLISH SUMMARY: This report details estimates carried out to assess the number of injecting drug users in Norway, including prevalence by age, sex and place of residence. Injecting drug users are widely considered to constitute one of the most vulnerable segments of the drug using population, exhibiting higher mortality and morbidity rates compared with other drug users and the wider public. They are more socially distressed, and problems associated with substance dependency appear to be more severe than among other drug users. Information on the size of the injecting population is essential for capacity planning in the health and social services and for interventions aimed at mitigating drug use. Three methods are used to estimate the size of the injecting population: a mortality multiplier; a community-level survey; and a multiple-indicator method. They were selected in light of available Norwegian data. There are not many good indicators for estimating prevalence and trends in the injecting population. Our estimates suggest that the 2004 population of injecting drug users in Norway ranged between 8,200 and 12,500. The upper limit is slightly higher than that obtained with the mortality multiplier method. The estimates provided by the other two methods are probably over-generous. As our indicators are relatively stable for the 2004-2005 period, our inferred estimate of the 2005 population also lies within the 8,200-12,500 range. Estimates derived from the mortality multiplier show a rising number of active injectors 1997-2000, followed by a dip in 2003 and a plateau 2004/5. Our estimates give therefore fewer active injectors today than around the turn of the century. The rise in the number of patients in substitution treatment (LAR) could explain the fall 2001-2003. Patient numbers continued to grow however in 2003-2005, without a concomitant reduction in the injecting population. This discrepancy could be explained either by substitution treatment drop outs, reverting to active drug use, or a higher influx of new injectors. Available data do not indicate, however, rising recruitment. There is a paucity of information on other therapies in Norway targeting drug injectors, but capacity here has probably remained stable while substitution treatment was being established. The female injecting population has probably fallen slightly since the early 1990s, from about 30-35 per cent to 25-30 per cent. Over the same period, average age has risen. Age of debut (first injection) has also increased, with newcomers exhibiting a wider age range than previously. The number of injecting drug users in Oslo did not rise from 1999 to 2001, contrary to the rest of Norway. And the estimated number of Oslo-based injectors also fell more sharply than in other areas after 2001, in compliance with the falling proportion of the injecting population in Oslo. In the rest of Norway, divided into three areas, the growth of 1999-2001 and decline of 2001-2005 were comparable with national trends. Although Oslo’s share of injectors fell after 1999, prevalence and associated problems are still more prominent here than elsewhere in the country.-
dc.language.isonoen
dc.publisherSIRUSen
dc.relation.ispartofseriesSIRUS-rapporten
dc.relation.ispartofseries2006/5en
dc.relation.urlhttp://www.sirus.no/internett/narkotika/publication/309.htmlen
dc.subjectVDP::Samfunnsvitenskap: 200en
dc.subject.meshSubstance Abuse, Intravenousen
dc.subject.meshOpioid-Related Disordersen
dc.subject.meshStatisticsen
dc.subject.meshNorwayen
dc.titleOmfang av sprøytemisbruk i Norgeno
dc.typepeer revieweden
dc.typeReporten
dc.contributor.departmentNorwegian Insitute for Alcohol and Drug Researchen
All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.